NCT06319287已完成2 期
A Phase 2a Multi-Center, Prospective, Randomized Controlled Study to Evaluate the Safety and Efficacy of Topically Applied PEP-TISSEEL in Subjects With Diabetic Foot Ulcers (DFU)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Rion Inc.
- 入组人数
- 59
- 试验地点
- 2
- 主要终点
- Wound Closure
研究概览
简要总结
This is a Phase 2a Multi-Center, Prospective, Randomized, Controlled Study aimed to evaluate the Safety and Efficacy of Topically Applied PEP-TISSEEL in Subjects with Diabetic Foot Ulcers (DFU)
详细描述
The objective of this multi-center, prospective, randomized controlled study is to evaluate the safety and efficacy of PEP-TISSEEL+ Standard of Care (SOC) compared to SOC only treatment in up to 60 subjects (30 subjects PEP-TISSEEL + SOC and 30 subjects SOC only), specifically for the treatment of their non-healing DFU.
Treatment for the PEP-TISSEEL+SOC arm is:
-
PEP-TISSEEL
-
Mepitel dressing followed by Tegaderm® (Mepilex can be used if subjects are allergic to Tegaderm)
-
3M Cavilon® (may be used on the borders prior to placing the Tegaderm or Mepilex)
-
Padded 3-layer secondary outer layer dressing (Profore (Smith and Nephew (Memphis, TN)); and
-
Offloaded with an offloading Controlled Ankle Movement (CAM) Boot (Foot Defender (Miami, FL) or Total Contact Cast (TCC))
-
Use of an alternate offloading device (e.g., Charcot Restraint Orthotic Walker (CROW) boot, custom shoe, etc.) may be approved on a case-by-case basis
Treatment for the Standard of Care (SOC) only arm is:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Open Label
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females ≥ 18 years of age
- •Properly obtained written informed consent
- •Documented history of Type I or Type II Diabetes Mellitus, requiring oral and/or insulin replacement therapy
- •The index ulcer is classified as Wagner grade 1 ulcer and remains Wagner 1 Grade between Screening and Randomization/Baseline visit (Visit 1 through Visit 3)
- •These ulcers are superficial, full-thickness ulcers limited to the dermis, not extending to the subcutaneous tissue
- •Area of index ulcer must be between 1 cm2 to 15 cm2 post debridement at screening and baseline
- •The index ulcer must be located anatomically on the foot with ≥ 50% of the wound area below the medial or lateral malleolus
- •Presence of a persistent nonhealing DFU for at least 4 weeks from Randomization and not more than 1 year that has failed to respond to SOC at any point during this timeframe
- •Adequate vascular perfusion as evidenced by one of the following:
- •Dorsal transcutaneous oxygen measurement (TCOM/TcPO2) measurement of
- •≥ 40 mmHg within 90 days of Screening (Visit 1 or 2)
- •Ankle Branchial Index (ABI) between 0.7 and 1.3 within 90 days of Screening (Visit 1 or 2) using the extremity on which the index ulcer is located
- •Arterial Doppler ultrasound evaluating for biphasic or triphasic dorsalis pedis and/or posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of > 0.6 is acceptable within 90 days of Screening (Visit 1 or 2)
- •The index ulcer has been offloaded with protocol defined offloading device during Screening (Run-In) period through Randomization/Baseline visit.
- •Must meet one of the following criteria:
- •a. Female subjects of Non-Child-Bearing Potential defined as: i. Postmenopausal for at least 1 year (Subject verbal confirmation acceptable), or surgically sterilized (i.e., hysterectomy or bilateral oophorectomy more than 3 months prior to Screening (Visit 1 or 2)), or ii. Bilateral tubal ligation more than 6 months prior to Screening (Visit 1 or 2), or iii. Must have a negative serum β-hCG pregnancy test at Visit 1 and not be breastfeeding prior to being administered with the study drug b. Male subjects of Non-Childbearing Potential are defined as those vasectomized subjects whose vasectomy was performed 6 months prior to Screening (Visit 1 or 2) or those diagnosed as sterile by a physician c. Females and Males of Childbearing Potential who practice an acceptable method of contraception defined as the use of any form of hormonal contraceptive, a barrier method with spermicide, condoms, intrauterine device, or abstinence from sexual intercourse starting at least 60 days prior to Screening and continuing at least 30 days following the last treatment.
- •Female will undergo a negative serum β-hCG pregnancy test at Visit 1 and an additional urine test at Baseline/Randomization (Visit 3 or Day 0) and must not be breastfeeding prior to being administered with the study drug
- •Ability to comply with the study protocol as per investigator discretion
排除标准
- •Actively undergoing chemotherapy treatment (localized radiation treatment is allowed if it is not on the DFU wound site and in remission based on scans, bloodwork or some other kind of test, such as a breast biopsy or a bone marrow biopsy)
- •Ulceration with exposed tendon, capsule, or bone
- •Suspicion of bone or joint infection by clinical or other criteria as per STONEES criteria below:
- •a. STONEES criteria for infection: i. size increase, ii. temperature elevation, iii. os (probe to bone) iv. new areas of breakdown v. exudative vi. erythema/edema vii. smell
- •Unable or unwilling to utilize the protocol defined offloading device
- •Subjects who have undergone endovascular or open revascularization of the index limb within the last 30 days from Screening.
- •Index ulcer has decreased in area by ≥ 30% between Screening (Visit 1) and Baseline visits
- •Any subject that is currently on/or requires oral, systemic or topical antibiotics, or is anticipated to require their use during the course of the study
- •Any subject that has vascular compromise requiring surgical intervention or has undergone vascular reconstruction or angioplasty less than 1 month prior to randomization. Any planned surgical procedures during the study participation
- •Serum Creatinine level > 3.0 mg/dL
- •Hemoglobin A1c (HbA1c) >12%
- •Aspartate Aminotransferase (AST, GOT) and/or Alanine Aminotransferase (ALT, GPT) >3x the upper limit of normal
- •Acute active Charcot foot
- •The location of the index ulcer is within 2 cm of any other ulcer
- •Any subject that would be unable to safely monitor the infection status of the index ulcer at home and return for scheduled visits
- •History of immunosuppression or taking immunosuppressive agents including systemic corticosteroids, except stable daily doses of 5 mg/day or less for chronic conditions for up to 5 days
- •Any subject with a life expectancy ≤ 6 months
- •Pregnancy, including a positive pregnancy test at Baseline, or lactation/breastfeeding at anytime
- •Use of investigational drugs or biologics within 28 days prior to screening (Visit 1 or 2)
- •History of a concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol
- •Known or suspected active abuse of alcohol, or non-prescription drugs
- •Participation in another interventional clinical study or study in the past 30 days of Screening (Visit 1 or 2) or concurrent participation in another interventional clinical study
- •Subjects who have untreated Hep C
- •Subjects who are HIV positive
- •Subjects on anticoagulation that are not maintained within the International Normalized Ratio (INR) of > 3.0
研究组 & 干预措施
PEP-TISSEEL+SOC
Active Comparator
Treatment for the PEP-TISSEEL+SOC arm is:
- PEP-TISSEEL
- Mepitel dressing followed by Tegaderm® (Mepilex can be used if subjects are allergic to Tegaderm)
- 3M Cavilon® (may be used on the borders prior to placing the Tegaderm or Mepilex)
- Padded 3-layer secondary outer layer dressing (Profore (Smith and Nephew (Memphis, TN)); and
- Offloaded with an offloading Controlled Ankle Movement (CAM) Boot (Foot Defender (Miami, FL) or Total Contact Cast (TCC)) Use of an alternate offloading device (e.g., Charcot Restraint Orthotic Walker (CROW) boot, custom shoe, etc.) may be approved on a case-by-case basis
干预措施: PEP (Purified Exosome Product) / TISSEEL (Biological)
Standard of Care
Sham Comparator
- Fibracol
- Mepitel dressing followed by Tegaderm (Mepilex can be used if subjects are allergic to Tegaderm)
- 3M Cavilon (may be used on the borders prior to placing the Tegaderm or Mepilex )
- Padded 3-layer secondary outer layer dressing (Profore (Smith and Nephew (Memphis, TN)) or equivalent); and
- Offloaded with an offloading CAM Boot (Foot Defender (Miami, FL) or TCC)
- Use of an alternate offloading device (e.g., Charcot Restraint Orthotic Walker (CROW) boot, custom shoe, etc.) may be approved on a case-by-case basis
干预措施: PEP (Purified Exosome Product) / TISSEEL (Biological)
结局指标
主要结局
Wound Closure
时间窗: 12 weeks
Complete wound closure (wound healing) by 12 weeks (efficacy; landmark analysis)
Safety
时间窗: 6 months
Count dose limiting toxicity events (incidence of treatment-emergent adverse event)
Complete Wound Closure
时间窗: 12 weeks
Complete wound closure (wound healing) by 12 weeks (efficacy; landmark analysis)
Dose Limiting Toxicities
时间窗: 12 week treatment + 3 month (12 weeks) non-dosing Safety Follow-Up
Count dose limiting toxicity events.
次要结局
- Percent Area Reduction of Wound at 12 Weeks(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis BChronic Hepatitis BNCT06425341Fujian Shengdi Pharmaceutical Co., Ltd.369
Unknown
2 期
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine TumorExtrapancreatic Neuroendocrine TumorNCT03204032Chinese Academy of Medical Sciences60
Unknown
2 期
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine TumorPancreatic Neuroendocrine TumorNCT03204019Chinese Academy of Medical Sciences60
终止
2 期
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive LabelNon-small Cell Lung CancerNCT02318368AVEO Pharmaceuticals, Inc.10
已完成
2 期
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid RecurrenceKeloidNCT04844840Sirnaomics29